Related references
Note: Only part of the references are listed.Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke et al.
LANCET (2022)
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
E. A. Rozeman et al.
NATURE MEDICINE (2021)
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).
Pasi A. Janne et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma
Laura Hueser et al.
CANCERS (2020)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu et al.
NATURE MEDICINE (2019)
Overexpression of HER2/HER3 and clinical feature of ovarian cancer
Ye Won Chung et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2019)
Antibody-Drug Conjugates for Cancer Treatment
John M. Lambert et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Understanding the biology of HER3 receptor as a therapeutic target in human cancer
Hui Lyu et al.
Acta Pharmaceutica Sinica B (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
Angela N. Bartley et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Jason Madore et al.
CLINICAL CANCER RESEARCH (2016)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
EGFR Modulates DNA Synthesis and Repair through Tyr Phosphorylation of Histone H4
Ruey-Hwang Chou et al.
DEVELOPMENTAL CELL (2014)
ERBB3 is required for metastasis formation of melanoma cells
S. Tiwary et al.
ONCOGENESIS (2014)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Nuclear HER3 is associated with favorable overall survival in uveal melanoma
Eric Trocme et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
HER2 testing in gastric cancer: a practical approach
Josef Rueschoff et al.
MODERN PATHOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
J. Tanizaki et al.
BRITISH JOURNAL OF CANCER (2011)
EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment
Gianmaria Liccardi et al.
CANCER RESEARCH (2011)
Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma
Mikiko Takikita et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
Kathryn Tworkoski et al.
MOLECULAR CANCER RESEARCH (2011)
NRG1/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation
Kristina Buac et al.
PIGMENT CELL & MELANOMA RESEARCH (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
The ERBB3 receptor in cancer and cancer gene therapy
G. Sithanandam et al.
CANCER GENE THERAPY (2008)
HER3 is a determinant for poor prognosis in melanoma
Markus Reschke et al.
CLINICAL CANCER RESEARCH (2008)
High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer
Mikiko Hayashi et al.
CLINICAL CANCER RESEARCH (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
ErbB-3 predicts survival in ovarian cancer
Berno Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Bin-Bing S. Zhou et al.
CANCER CELL (2006)
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth
CW Gregory et al.
CLINICAL CANCER RESEARCH (2005)
Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
AA Memon et al.
BRITISH JOURNAL OF CANCER (2004)
Biologic and therapeutic role of HER2 in cancer
S Ménard et al.
ONCOGENE (2003)
Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer
CJ Witton et al.
JOURNAL OF PATHOLOGY (2003)
Share Paper
